ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
14 Mars 2024 - 6:00PM
Business Wire
- Validation of CER-001 development in ophthalmology
- Key milestone to launch clinical study in a new severe
indication
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible)
(Paris:ABNX), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world’s only natural recombinant apoA-I, announces a nearly €1
million innovation grant from Bpifrance. The aim of this grant is
to support the development of drug candidate CER-001 in the
treatment of a severe indication in ophthalmology.
This grant will help finance studies on the CER-001 drug
candidate. Payment will be made in two instalments, once
development has begun and ABIONYX Pharma has made the corresponding
investment in its 100% ophthalmology subsidiary, Apogeye Pharma.
The grant will be repayable at 0% on condition of success, from the
last quarter of 2026 to the first quarter of 2031.
The ophthalmic preclinical studies carried out to date have been
promising, demonstrating a suitable pharmacokinetic profile and
convincing pharmacological results. The data support the launch of
a program in a severe ophthalmology indication with a new
innovative mechanism of action. ABIONYX Pharma would like to thank
Bpifrance for its long-standing support and confidence in the
Company's development of the world's only recombinant apoA-I.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine, its bioproduct
suppliers and its shareholders, the Company innovates on a daily
basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240314019012/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
